Tagrisso
E505479
Tagrisso is a targeted cancer therapy (osimertinib) used primarily to treat certain types of EGFR-mutated non-small cell lung cancer.
Statements (50)
| Predicate | Object |
|---|---|
| instanceOf |
EGFR inhibitor
ⓘ
pharmaceutical drug ⓘ targeted cancer therapy ⓘ tyrosine kinase inhibitor ⓘ |
| approvedBy |
European Medicines Agency
NERFINISHED
ⓘ
U.S. Food and Drug Administration NERFINISHED ⓘ |
| belongsToClass | third-generation EGFR tyrosine kinase inhibitors ⓘ |
| canPenetrate | blood–brain barrier ⓘ |
| developedBy | AstraZeneca NERFINISHED ⓘ |
| FDAApprovalYear | 2015 ⓘ |
| hasActiveIngredient | osimertinib ⓘ |
| hasATCCode | L01EB10 ⓘ |
| hasBioavailability | high oral bioavailability ⓘ |
| hasBlackBoxWarning |
QT interval prolongation
ⓘ
interstitial lung disease ⓘ |
| hasChemicalFormula | C28H33N7O2 ⓘ |
| hasCommonAdverseEffect |
back pain
ⓘ
cough ⓘ decreased appetite ⓘ diarrhea ⓘ dry skin ⓘ fatigue ⓘ nausea ⓘ paronychia ⓘ pruritus ⓘ pyrexia ⓘ rash ⓘ stomatitis ⓘ |
| hasDosageForm | tablet ⓘ |
| hasHalfLife | approximately 48 hours ⓘ |
| hasInternationalNonproprietaryName | osimertinib ⓘ |
| hasLegalStatusInEU | prescription only ⓘ |
| hasLegalStatusInUS | prescription only ⓘ |
| hasPregnancyRisk | can cause fetal harm ⓘ |
| hasRouteOfAdministration | oral ⓘ |
| indicatedFor |
EGFR-mutated non-small cell lung cancer
ⓘ
adjuvant treatment of EGFR-mutated non-small cell lung cancer after tumor resection ⓘ first-line treatment of EGFR-mutated metastatic non-small cell lung cancer ⓘ metastatic EGFR T790M-positive non-small cell lung cancer ⓘ non-small cell lung cancer ⓘ |
| isPrescriptionOnly | true ⓘ |
| isSmallMolecule | true ⓘ |
| isSubstrateOf |
CYP3A4
NERFINISHED
ⓘ
CYP3A5 ⓘ |
| mechanismOfAction | irreversible EGFR tyrosine kinase inhibitor ⓘ |
| targets |
EGFR L858R mutant
NERFINISHED
ⓘ
EGFR T790M mutant ⓘ EGFR exon 19 deletion mutant ⓘ epidermal growth factor receptor NERFINISHED ⓘ |
| usedFor | treatment of brain metastases in EGFR-mutated non-small cell lung cancer ⓘ |
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.